Tumor cells in the embolized territory

Tumor cells in the embolized territory describes the malignant cell population residing within a region of tissue where the blood supply has been intentionally obstructed, typically via Transarterial Chemoembolization (TACE) (StatPearls, 2023). This designation is clinical and anatomical rather than a specific molecular entity such as a receptor or enzyme. The therapeutic strategy involves the delivery of embolic agents to the tumor-feeding arteries, which induces ischemia and hypoxia while simultaneously providing a high local concentration of chemotherapy (NCI, 2024). By blocking the arterial supply, the embolic agents trap cytotoxic drugs—such as doxorubicin or cisplatin—within the tumor microenvironment, extending their contact time with the cancer cells (PubMed, 25083231). The dual mechanism of nutrient deprivation and DNA damage aims to induce extensive tumor necrosis while minimizing systemic side effects. This approach is primarily utilized for patients with unresectable hepatocellular carcinoma or liver-dominant metastatic disease. Monitoring of the target's response is typically performed using imaging criteria such as mRECIST and serum biomarkers like alpha-fetoprotein (AFP) (NIH, 2022). Safety concerns associated with targeting these cells include post-embolization syndrome, potential liver failure, and risks of non-target embolization to healthy tissues.

Other names

Embolized tumor cellsTACE target cellsIschemic tumor cellsTarget cells in chemoembolization

Ischemia-induced necrosis combined with localized cytotoxic chemotherapy